How much has Pacira BioSciences raised?
Pacira BioSciences is a public company (Nasdaq: PCRX), so the most useful current funding read is its filings, revenue scale, cash flow, guidance, and acquisition capacity rather than private round totals.
- Total raised
- Public company; private total not the current constraint
- Disclosed rounds
- Pre-IPO/private history plus public filings
- Latest round
- Public-market financing and operating cash flow
- Latest valuation
- Nasdaq: PCRX
- First raised
- 2006
- Notable backer
- Public shareholders
Pacira BioSciences's funding rounds
Pacira BioSciences's capital path moved from founding and growth capital into public-company financing.
- 2006FoundedPacira is formed around DepoFoam and non-opioid pain management assets.
- 2011IPOPacira lists publicly on Nasdaq.
- 2018Myoscience acquisitionPacira adds iovera cold-therapy technology.
- 2021Flexion acquisitionPacira acquires ZILRETTA and broadens osteoarthritis pain exposure.
- 2026Q1 2026 resultsPacira reports $177M of first-quarter revenue.
How much has Pacira BioSciences raised in total?
Pacira BioSciences is best analyzed as a public company as of June 2026. Any pre-IPO venture or private-equity history is less useful for current selling than the company's listed status, revenue base, cash generation, debt capacity, and investor commitments.
The current scale marker is $726.4M 2025 revenue; $177M Q1 2026 revenue. That tells sellers the company can fund enterprise purchases, but those purchases must survive budget ownership, procurement, security, compliance, and ROI review.
Who are Pacira BioSciences's investors?
The relevant investor base is the public shareholder base behind Nasdaq: PCRX. Management teams at this stage are accountable to public-market expectations for growth, margin, cash flow, guidance, and risk control.
That accountability affects buying behavior: projects tied to reported metrics, margin expansion, regulatory readiness, or customer growth are easier to justify than speculative tooling.
Why did valuation or capital priorities move?
Valuation for a public healthcare company moves with growth, margins, reimbursement, utilization, clinical evidence, customer retention, regulatory risk, and capital-market sentiment. Pacira BioSciences's latest public materials emphasize $726.4M 2025 revenue; $177M Q1 2026 revenue, which is the clearest factual anchor for current account planning.
For seller strategy, avoid treating valuation as the budget. Translate the company's stated operating priorities into a business case owned by a specific executive function.
Is Pacira BioSciences profitable, and will it need more capital?
Profitability and capital needs should be read from the latest annual report, quarterly results, cash-flow statement, and guidance. Public healthcare and life-science companies can have revenue scale while still prioritizing profitability, cash preservation, restructuring, R&D, or commercial expansion.
The safe sales assumption is mature budget governance: finance will ask why the project matters now, what metric it moves, and how implementation risk is controlled.
What does Pacira BioSciences's funding mean if you sell into them?
The seller signal is buying capacity with a high proof bar. Pacira BioSciences can fund software, data, services, infrastructure, compliance, clinical, and go-to-market projects when they match a board-visible or executive-visible priority.
Procurement is likely to favor vendors with healthcare references, security documentation, integration readiness, implementation support, and clear commercial terms.
As of June 2026.Sources:Pacira Q1 2026 resultsPacira investor presentation
Pacira BioSciences — frequently asked questions
